Live Feed

Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19% First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US

SCHEDULE 13G - Optimum Communications, Inc. (0001702780) (Subject)

144 - D-Wave Quantum Inc. (0001907982) (Subject)

BENTON HARBOR, Mich., June 12, 2026 /PRNewswire/ -- Whirlpool Corporation (NYSE: WHR) ("Whirlpool" or the "Company") is releasing early results as of 5:00 p.m., Central European time (11:00 a.m., New York City time), on June 12, 2026 (the "Early Tender Expiration"), of its previously announced (i) tender offer (the "Tender Offer") to purchase for cash any and all of the outstanding 1.250% Notes due 2026 (the "2026 Notes") and 1.100% Notes due 2027 (the "2027 Notes" and together with the 2026 Notes, the "Notes") of Whirlpool Finance Luxembourg S.à r.l., a private limited liability company (société à responsabilité limitée) organized under the laws of the Grand Duchy of Luxembourg (the "Issuer

144 - Netskope Inc (0002063196) (Subject)

144/A - Arista Networks, Inc. (0001596532) (Subject)

144/A - Arista Networks, Inc. (0001596532) (Subject)

144/A - Arista Networks, Inc. (0001596532) (Subject)

144/A - Arista Networks, Inc. (0001596532) (Subject)

144 - Viant Technology Inc. (0001828791) (Subject)

SCHEDULE 13D - STANDARD BIOTOOLS INC. (0001162194) (Subject)

All ECAT-Approved Trustees Will Remain in Place BlackRock Advisors, LLC ("BlackRock") announced today the final certified voting results of the 2026 Annual Meeting of Shareholders of BlackRock ESG Capital Allocation Term Trust (NYSE:ECAT) (the "Fund"). All nine of the Fund's unanimously approved nominees standing for re-election, Cynthia L. Egan, Lorenzo A. Flores, Stayce D. Harris, R. Glenn Hubbard, W. Carl Kester, John M. Perlowski, Robert Fairbairn, J. Phillip Holloman and Arthur P. Steinmetz, will continue to serve on the Board of Trustees (the "Board"). Each nominee received more support than any dissident nominee, reflecting strong shareholder support for the Board's oversight of

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrantsSEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced the closing of its previously announced registered direct offering of 1,363,637 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,363,637 shares of Common Stock and short-term Series B warrants to pu

6-K - Intercorp Financial Services Inc. (0001615903) (Filer)

ORLANDO, Fla., June 12, 2026 (GLOBE NEWSWIRE) -- Gencor Industries, Inc. (the "Company" or "Gencor") (NYSE:GENC) announced today net revenue for the quarter ended March 31, 2026 was $33,799,000 compared with $38,204,000 net revenue for the quarter ended March 31, 2025. The decrease in net revenue was primarily due to lower contract equipment revenues recognized over time and associated freight revenue, which resulted from the timing of orders and shipments. As a percentage of net revenue, gross profit margins increased 200 basis points to 31.7% in the quarter ended March 31, 2026, compared to 29.7% in the quarter ended March 31, 2025. Product engineering and development expenses decreased

NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, the Company)), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA). "Tivoxavir marboxil demonstrated potent efficacy in three animal models of highly pathogenic avian influenza and a pharmacokinetic profile consistent with its use for bird flu treatment and prevention," said C. David Pauza, PhD Chief Science

NORTH LIBERTY, Iowa, June 12, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Heartland Express, Inc. (NASDAQ:HTLD) announced today the declaration of a regular quarterly cash dividend. The $0.02 per share dividend will be paid on July 6, 2026, to shareholders of record at the close of business on June 23, 2026. We currently estimate that a total of $1.6 million will be paid on the Company's approximate seventy-eight million shares of common stock. This is the Company's ninety-second consecutive quarterly cash dividend. With the payment of this dividend, the Company will have paid a total of $564.5 million in cash dividends, including four special dividends since the dividend program wa

8-K - Real Asset Acquisition Corp. (0002052161) (Filer)

F-3 - Himalaya Shipping Ltd. (0001959455) (Filer)

8-K - Perfect Moment Ltd. (0001849221) (Filer)